12:00 AM
 | 
Jan 31, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Avodart dutasteride regulatory update

FDA issued a complete response for an sNDA from GlaxoSmithKline for Avodart dutasteride to reduce the risk of prostate cancer in men at increased...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >